FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4242453976> ?p ?o ?g. }

• W4242453976 endingPage "1073" @default.
• W4242453976 startingPage "1070" @default.
• W4242453976 abstract "We evaluated by means of a bioassay the efficacy of 4 different antibiotics administered in a prophylactic dose to children with vesicoureteral reflux.A total of 159 urine samples from 53 children taking prophylactic antibiotics with proved vesicoureteral reflux were tested. The children were divided into 4 groups according to the antibiotic given, which included nalidixic acid, cephalexin, cotrimoxazole and cefixime. Urine samples were collected in the morning, at noon and in the evening, and each sample was bioassayed for growth inhibition of a standard Escherichia coli. The urine volume used was specifically determined for each antibiotic, and growth inhibition by this specific volume was equivalent to that produced by standard diffusion disks. In addition, the specific gravity, which reflected urinary concentration of each sample, was measured.Mean patient age plus or minus standard deviation of the 4 groups was 53 +/- 41 for nalidixic acid, 23 +/- 34 for cephalexin, 55 +/- 35 for cotrimoxazole and 47 +/- 35 months for cefixime, respectively. In children less than 2 years old specific gravity was higher in the morning (1.021 +/- 0.0006 versus 1.0008 +/- 0.0004 at 8 a.m. and 2 p. m., respectively, p <0.05). In contrast, in children older than 4 years the specific gravity was higher in the afternoon and evening hours (1.019 +/- 0.003 versus 1.007 +/- 0.003 at 2 p.m. and 8 a.m., respectively, p <0.05). The percentage of patients who demonstrated growth inhibition in all 3 samples of the test day was 7%, 6%, 69% and 44% for nalidixic acid, cephalexin, cotrimoxazole and cefixime, respectively (p <0.001 for cotrimoxazole and cefixime versus nalidixic acid and cephalexin. Divided into morning, noon and evening, the percentage of samples that demonstrated growth inhibition was 85.7%, 21.4% and 7.1% for nalidixic acid, 37.5%, 12. 5% and 6.3% for cephalexin, 100%, 92.3% and 76.9% for cotrimoxazole and 100%, 77.7% and 55.5% for cefixime, respectively. A direct correlation was found between specific gravity and growth inhibition (r = 0.55, p <0.001).Urine concentration during the day is dependent on age with older children having more concentrated urine in the latter part of the day. Growth inhibition is enhanced by concentrated urine. Compared to nalidixic acid and cephalexin, cotrimoxazole and cefixime produce a sustained bactericidal effect for about 60% of a 24-hour day due to the longer half-life." @default.
• W4242453976 created "2022-05-12" @default.
• W4242453976 creator A5002448359 @default.
• W4242453976 creator A5008299756 @default.
• W4242453976 creator A5012512596 @default.
• W4242453976 creator A5024687076 @default.
• W4242453976 creator A5066314292 @default.
• W4242453976 creator A5074825040 @default.
• W4242453976 creator A5091506223 @default.
• W4242453976 date "2000-09-01" @default.
• W4242453976 modified "2023-10-15" @default.
• W4242453976 title "A BIOASSAY EVALUATION OF THE URINARY ANTIBACTERIAL EFFICACY OF LOW DOSE PROPHYLACTIC ANTIBIOTICS IN CHILDREN WITH VESICOURETERAL REFLUX" @default.
• W4242453976 cites W1563611240 @default.
• W4242453976 cites W1970805851 @default.
• W4242453976 cites W1972114044 @default.
• W4242453976 cites W1992401227 @default.
• W4242453976 cites W2003850372 @default.
• W4242453976 cites W2010430975 @default.
• W4242453976 cites W2024233074 @default.
• W4242453976 cites W2033870320 @default.
• W4242453976 cites W2064494689 @default.
• W4242453976 cites W2148540702 @default.
• W4242453976 cites W2166193275 @default.
• W4242453976 cites W2168419678 @default.
• W4242453976 cites W2407180454 @default.
• W4242453976 cites W2414011801 @default.
• W4242453976 cites W2423233457 @default.
• W4242453976 cites W4248816181 @default.
• W4242453976 cites W4320800519 @default.
• W4242453976 doi "https://doi.org/10.1097/00005392-200009020-00037" @default.
• W4242453976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10958743" @default.
• W4242453976 hasPublicationYear "2000" @default.
• W4242453976 type Work @default.
• W4242453976 citedByCount "2" @default.
• W4242453976 countsByYear W42424539762013 @default.
• W4242453976 countsByYear W42424539762018 @default.
• W4242453976 crossrefType "journal-article" @default.
• W4242453976 hasAuthorship W4242453976A5002448359 @default.
• W4242453976 hasAuthorship W4242453976A5008299756 @default.
• W4242453976 hasAuthorship W4242453976A5012512596 @default.
• W4242453976 hasAuthorship W4242453976A5024687076 @default.
• W4242453976 hasAuthorship W4242453976A5066314292 @default.
• W4242453976 hasAuthorship W4242453976A5074825040 @default.
• W4242453976 hasAuthorship W4242453976A5091506223 @default.
• W4242453976 hasConcept C104488531 @default.
• W4242453976 hasConcept C121332964 @default.
• W4242453976 hasConcept C126322002 @default.
• W4242453976 hasConcept C126894567 @default.
• W4242453976 hasConcept C1276947 @default.
• W4242453976 hasConcept C19720800 @default.
• W4242453976 hasConcept C2775876089 @default.
• W4242453976 hasConcept C2776476923 @default.
• W4242453976 hasConcept C2777609623 @default.
• W4242453976 hasConcept C2778243283 @default.
• W4242453976 hasConcept C2778512257 @default.
• W4242453976 hasConcept C2779134260 @default.
• W4242453976 hasConcept C2780026642 @default.
• W4242453976 hasConcept C43270747 @default.
• W4242453976 hasConcept C501593827 @default.
• W4242453976 hasConcept C54355233 @default.
• W4242453976 hasConcept C64778159 @default.
• W4242453976 hasConcept C71924100 @default.
• W4242453976 hasConcept C77411442 @default.
• W4242453976 hasConcept C86803240 @default.
• W4242453976 hasConcept C89423630 @default.
• W4242453976 hasConceptScore W4242453976C104488531 @default.
• W4242453976 hasConceptScore W4242453976C121332964 @default.
• W4242453976 hasConceptScore W4242453976C126322002 @default.
• W4242453976 hasConceptScore W4242453976C126894567 @default.
• W4242453976 hasConceptScore W4242453976C1276947 @default.
• W4242453976 hasConceptScore W4242453976C19720800 @default.
• W4242453976 hasConceptScore W4242453976C2775876089 @default.
• W4242453976 hasConceptScore W4242453976C2776476923 @default.
• W4242453976 hasConceptScore W4242453976C2777609623 @default.
• W4242453976 hasConceptScore W4242453976C2778243283 @default.
• W4242453976 hasConceptScore W4242453976C2778512257 @default.
• W4242453976 hasConceptScore W4242453976C2779134260 @default.
• W4242453976 hasConceptScore W4242453976C2780026642 @default.
• W4242453976 hasConceptScore W4242453976C43270747 @default.
• W4242453976 hasConceptScore W4242453976C501593827 @default.
• W4242453976 hasConceptScore W4242453976C54355233 @default.
• W4242453976 hasConceptScore W4242453976C64778159 @default.
• W4242453976 hasConceptScore W4242453976C71924100 @default.
• W4242453976 hasConceptScore W4242453976C77411442 @default.
• W4242453976 hasConceptScore W4242453976C86803240 @default.
• W4242453976 hasConceptScore W4242453976C89423630 @default.
• W4242453976 hasLocation W42424539761 @default.
• W4242453976 hasLocation W42424539762 @default.
• W4242453976 hasOpenAccess W4242453976 @default.
• W4242453976 hasPrimaryLocation W42424539761 @default.
• W4242453976 hasRelatedWork W1964100181 @default.
• W4242453976 hasRelatedWork W1997915932 @default.
• W4242453976 hasRelatedWork W2004770570 @default.
• W4242453976 hasRelatedWork W2007649676 @default.
• W4242453976 hasRelatedWork W2058498443 @default.
• W4242453976 hasRelatedWork W2060578086 @default.
• W4242453976 hasRelatedWork W2072124510 @default.
• W4242453976 hasRelatedWork W2072308473 @default.

• next